Urgent medical challenges demand innovative solutions. Your support fuels our lab’s cutting edge research to make groundbreaking discoveries. Together, we can transform the future of medicine and train the next generation of scientific leaders.
Join us in bringing hope to those in need.
Contact Dr. Ganesh Thakur to learn how your contribution can drive progress to make a real difference.
Our thanks to
Current Funding Information
- 1R01DA059985-01A1
Title: Selective Positive Allosteric Modulators of a4b2 Nicotinic Receptors
Date: 08/01/2024-05/31/2029
This proposal will develop novel chemical probes to target the nicotinic acetylcholine receptor (nAChR). The α4β2 nAChR presents in two distinct isoforms: the high sensitivity α42β23 nAChR, and the low sensitivity α43β22 nAChR. Our recently published findings have led to the hypothesis that drugs selectively targeting the high sensitivity α42β23 nAChR may provide a novel, previously undefined understanding of nicotine’s actions, and thus, the chemical probes derived from these studies may thereby lead to the development of more efficacious therapeutics to treat nicotine dependence in humans. - Canadian Institutes of Health Research (CIHR)
Title: Development of Novel Type 1 Cannabinoid Receptor Positive Allosteric Modulators for Infantile Spasms
Date: 05/01/2020- 05/30/2025
This project examines the development of CB1 receptor positive allosteric modulators (PAMs) and their possible use in the treatment of Infantile Spasms, a debilitating form of epilepsy that occurs mainly in the young for which current treatments are largely inadequate.
Recently Completed Grants
- 2R01GM057481-17 NIH/NIGMS
Title: Targeting the Alpha7 nAChR for Therapeutic Effects
Date: 03/01/2020- 02/28/2024 - RO1HL059949-23 NIH/NHLBI
Title: Structural Determinants of PIP2 Regulation
Date: 07/01/2020- 06/30/2024 - 1R01 EY024717-01/NIH-NEI
Title: A Novel Pharmacotherapy for Glaucoma
Date: 09/01/2014- 08/31/2021 (NCE) - R43MH103936 NIH/NIMH
Title: Novel treatment of posttraumatic stress disorder (PTSD)
Date: 08/01/2014-07/31/2016 - RO3 DA027113 NIH/NIDA
Title: Allosteric Modulators of CB1 Cannabinoid Receptor
Date: 08/01/2009-07/31/2013 - R01CA206028 NIH/NCI
Title: (PQ9) Mitigation of Chemotherapy Induced Peripheral Neuropathy
Date: 04/15/2016-03/31/2017 - R01DA026795 NIH/NIDA
Title: Novel Medications for Cannabis Dependence
Date: 07/15/2009- 05/31/2014
Empowered by:
- Daicel Chiral Technologies
- Agilent Technologies
- BUCHI
- Biotage
- Heidolph
- CEM Corporation
- Fisher Scientific
- Chemglass
- Thermo Fisher Scientific
- Combi-Blocks
- Sigma Aldrich
- Ambeed